Blood cancer Clinical Trials in New Haven, CT
As of June 2026, 51 paid clinical trials are recruiting for Blood cancer in New Haven, Connecticut. Blood cancer trials investigate CAR-T cell therapies, bispecific antibodies, BTK and BCL-2 inhibitors, and novel combinations across leukemias, lymphomas, myeloma, and myelodysplastic syndromes. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
51 clinical trials for Blood cancer
·Clear filters·↓ Download CSVA Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Hyperfractionated Dual Equivalent Fractionated Radiation Therapy
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
Revumenib in Combination With 7+3 + Midostaurin in AML
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
About research studies in New Haven
New Haven has approximately 909 recruiting research studies across a wide range of therapeutic areas. Connecticut hosts a diverse network of universities, academic medical centers, and community hospitals that run clinical trials across oncology, cardiology, neurology, and many other therapeutic areas.
Top Research Study Locations in New Haven
Researchers run research studies in New Haven, CT at 25 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Yale University | Acute Myeloid Leukemia, Alcohol Use Disorder, Stage IV Lung Cancer AJCC v8 | 275 |
| Yale Cancer Center | Advanced Solid Tumor, Breast Cancer, NSCLC | 75 |
| Yale University School of Medicine | Alzheimers Disease, Alzheimers Disease, Familial, Colorectal Cancer | 64 |
| Yale New Haven Hospital | Heart Failure, Ischemic Stroke, Multiple Myeloma | 62 |
| Yale School of Medicine | Epilepsy, Epilepsy (Treatment Refractory), Hemoglobinopathies | 43 |
| Smilow Cancer Center/Yale-New Haven Hospital | Malignant Solid Neoplasm, Ovarian Carcinoma, Plasma Cell Myeloma | 24 |
| Yale-New Haven Hospital | Breast Cancer, Myasthenia Gravis, Acute Ischemic Stroke | 14 |
| Connecticut Mental Health Center | Borderline Personality Disorder, Alcohol Use, Alcohol Use Disorder | 11 |
| Yale | ALL, Adult, AML, Acute Gastrointestinal Bleeding | 10 |
| Yale Child Study Center | Speech, Anxiety Disorder of Adolescence, Autism | 9 |
| Smilow Cancer Hospital at Yale New Haven | Advanced Solid Tumor, AML, AML With Mutated NPM1 | 8 |
| GSK Investigational Site | HIV Infections, Colonic Neoplasms, Gastrointestinal Neoplasms | 7 |
| Yale New Haven Health | Chronic Kidney Diseases, Claudication, Critical Limb Ischemia | 7 |
| Yale University, Yale Cancer Center | Breast Cancer, Endometrial Cancer, Ovarian Cancer | 7 |
| Musical Intervention Studios | COVID-19, Mental Health Issue, Alzheimer Disease | 6 |
| Yale New Haven Children's Hospital | Acute Liver Failure, Acute Liver Injury, Acute Respiratory Distress Syndrome | 6 |
| BLOOM | COVID-19, Mental Health Issue | 5 |
| Yale New Haven Health System | Aortic Stenosis, Heart Failure, ATTR Amyloidosis With Cardiomyopathy | 5 |
| Clinical Trial Site | Advanced Solid Cancer, Cerebral Amyloid Angiopathy, Generalized Myasthenia Gravis | 4 |
| Pfizer Clinical Research Unit - New Haven | Healthy, Drug Interaction, Healthy Adults | 4 |
| Smilow Cancer Hospital | Sickle Cell Disease, Glioma, Malignant, Hemoglobinopathies | 4 |
| Smilow Cancer Hospital - Yale New Haven Health | Breast Cancer, Advanced Non-Small Cell Lung Cancer, Advanced/Metastatic Solid Tumors | 4 |
| Yale University Cancer Center | Advanced Solid Tumor, Advanced Solid Tumors, Anal Squamous Cell Carcinoma | 4 |
| Yale University Yale Cancer Center | Advanced Solid Tumor, Advanced Solid Tumors, B Cell Lymphoma | 4 |
| Yale-New Haven Hospital-Yale Cancer Center | Advanced Breast Cancer, Breast Cancer, CRC | 4 |
Active & Upcoming Studies in New Haven (2026)
Recruiting trials in New Haven grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (334 active studies)
- A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 ) · Phase 1 · Eli Lilly and Company
- IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) · Phase 3 · Ono Pharmaceutical Co., Ltd.
Neurology & pain (50 active studies)
- COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE" · Phase 3 · Yale University
- Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up · Epiminder America, Inc.
Cardiovascular (39 active studies)
Diabetes & metabolic (37 active studies)
- A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes · Phase 3 · Novo Nordisk A/S
- A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients · Phase 1, Phase 2 · Yale University
Mental health & behavior (29 active studies)
- A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients · Phase 1, Phase 2 · Yale University
- Multi-Site Trial of Tirzepatide for Smoking Cessation · Phase 2 · University of Southern California
HIV / STI (12 active studies)
- RESTORE Study R61 Phase: Recovery and Engagement for Stimulant Users on Re-entry · University of Texas Southwestern Medical Center
- Integrating PrEP Decision Making Into Counseling in Sexual and Reproductive Health Clinics · Yale University
Vaccines (11 active studies)
Pediatric (9 active studies)
- A Virtual Reality E-cigarette Prevention and Emotion Regulation Intervention for Adolescents · Yale University
- Human Milk Concentrating Device to Optimize Mother's Own Milk · Mother's Milk is Best
Common conditions studied in New Haven
- Breast Cancer (24 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Advanced Solid Tumor (23 active studies). Recruiting Advanced Solid Tumor studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Alcohol Use Disorder (15 active studies). Alcohol use disorder trials evaluate GLP-1 agonists, novel pharmacotherapies, and digital therapeutics as adjuncts to behavioral treatment.
- Heart Failure (13 active studies). Heart failure trials explore SGLT-2 inhibitors, novel myosin modulators, and device-based therapies for both reduced and preserved ejection fraction.
- Opioid Use Disorder (13 active studies). Opioid use disorder research tests extended-release medications, novel pharmacotherapies, and harm-reduction interventions.
- Acute Myeloid Leukemia (12 active studies). Leukemia trials evaluate targeted inhibitors, CAR-T cell therapies, and novel combinations for acute and chronic forms of the disease.
Leading research sponsors in New Haven
- Yale University
- National Cancer Institute (NCI)
- Merck Sharp & Dohme LLC
- Children's Oncology Group
- SWOG Cancer Research Network
Local regulations and guidelines
Clinical trials in Connecticut are governed by U.S. Food and Drug Administration (FDA) regulations, Office for Human Research Protections (OHRP) standards, and federal HIPAA privacy rules. Every study is reviewed by an Institutional Review Board (IRB) to protect participant safety and ensure informed consent. Connecticut research additionally follows state public health department oversight and any applicable state privacy statutes.
Compensation & what to expect
- How payment typically works
- Compensation is most often provided through reloadable electronic study cards or direct deposit, paid out per completed visit rather than as a lump sum. Amounts vary by the time required, the number of visits, and the study's complexity — overnight stays and inpatient pharmacology studies generally pay more than short outpatient surveys. The exact amount is disclosed in writing during informed consent before any visit.
- Healthy volunteers
- Healthy participants aged 18 and older can earn compensation by joining vaccine, pharmacology, and biomarker studies in New Haven. These trials check how a new drug or vaccine behaves in healthy bodies before later-phase testing. Many sites maintain a healthy-volunteer registry so you hear about new opportunities first.
- What's included beyond payment
- Most trials cover study-related medical care at no cost — physical exams, lab work, imaging, the investigational treatment itself, and follow-up visits with the research team. Insurance is not required to participate. Free check-ups and access to specialists are common reasons participants return for additional studies.
- Travel and time
- Many sponsors reimburse travel, parking, mileage, and lost wages for visit days. Long-running studies and trials that require frequent visits often raise stipends accordingly. Ask the study coordinator for the visit schedule and reimbursement policy before you commit.
- Asking about compensation
- Compensation is set per protocol and per site, so figures are not published in trial registries. The fastest way to confirm payment for a specific study is to contact the recruiting site listed on the study record. Coordinators are accustomed to this question and will quote the per-visit and total amounts up front.
How to find a clinical trial in New Haven
Hipa.ai aggregates every recruiting study in New Haven from ClinicalTrials.gov and refreshes the list daily. Use the filters above to narrow by condition, facility, age, phase, or healthy-volunteer eligibility, then click any study title to view full details — eligibility criteria, intervention, location, and sponsor contact information. To enroll, reach out to the central study contact listed on the study detail page; the research coordinator will walk you through the screening process.
Frequently asked questions
How many paid clinical trials are currently recruiting in New Haven?
There are approximately 909 recruiting clinical trials in New Haven, Connecticut listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in New Haven pay participants?
Most recruiting trials in New Haven compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in New Haven?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in New Haven?
The most common conditions under active study in New Haven include Breast Cancer (24), Advanced Solid Tumor (23), Alcohol Use Disorder (15), Heart Failure (13), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in New Haven?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in New Haven on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in New Haven?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in New Haven?
Recruiting research sites in New Haven include Yale University, Yale Cancer Center, Yale University School of Medicine, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in New Haven right now?
The largest active categories in New Haven are Cancer & tumors (334), Neurology & pain (50), Cardiovascular (39). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.